Safety and tolerability of grass pollen tablets in sublingual immunotherapy - A phase-1 study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 10, 2006, Pages 1173-1176

  Larsen, T H ^a   Poulsen, L K ^a   Melac, M ^b   Combebias, A ^b   Andre, C ^b   Malling, H J ^a  

^a Rigshospitalet   (Denmark)

^b Stallergenes SA   (France)

Author keywords

Adverse events; Dose response; Grass pollen; Seasonal allergic rhinitis; Sublingual immunotherapy

Indexed keywords

FEXOFENADINE; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; PREDNISOLONE;

ADULT; ALLERGIC RHINITIS; ARTICLE; BLISTER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; EAR PRURITUS; ELECTROCARDIOGRAM; EYE DISEASE; EYE REDNESS; FACE EDEMA; FATIGUE; FEMALE; HUMAN; IMMUNOTHERAPY; LABORATORY TEST; MALE; MOUTH PAIN; ORAL PRURITUS; OROPHARYNX SWELLING; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SKIN TEST; SWELLING; THROAT IRRITATION; TONGUE SWELLING; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748324517     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01203.x     Document Type: Article

References (11)

1. Malling HJ. Allergen-specific immunotherapy in allergic rhinitis. Curr Opin Allergy Clin Immunol 2001;1:43-46.
2. Malling HJ. Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results. Curr Opin Allergy Clin Immunol 2004;4:539-542.
3. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:229-234.
4. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl. 44):1-42.
5. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. ARIA workshop report. J Allergy Clin Immunol 2001;108(Suppl.):147-276.
6. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998;53:493-498.
7. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45-53.
8. Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabie-Bouchat YP et al. Safety and clinical efficacy of rush sublingual cypress immunotherapy: preliminary results. Allergy 2002; 57(Suppl. 73):70.
9. André C. Safety of high-dose ultrarush sublingual immunotherapy in children. Amsterdam, the Netherlands: XXIII EAACI Congress, 2004:139-140 (abstract),
10. Dreborg S, Frew A. EAACI Position Paper: allergen standardization and skin tests. Allergy 1993;48(Suppl. 14):49-82.
11. Djurup R, Osterballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984;39:433-441.